CMS Restricts Coverage For Devices More Than Drugs, Study Finds
Executive Summary
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.
You may also be interested in...
FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says
Exact Sciences, one of the first companies to volunteer for a pilot program launched in 2011 testing FDA-CMS parallel review, says its experience with the process so far is very positive. Agency officials are planning to review experiences with the program to make improvements.
CMS Policy Sets Boundaries On Transcatheter Valve Procedure
New Medicare coverage policy for transcatheter aortic valve replacement is a significant step for the nascent procedure and a possible window into how the agency will address future high-profile, early-stage technologies.
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
FDA and CMS are seeking device companies with innovative technologies to participate in the first test of "parallel," or simultaneous, pre-market approval and Medicare coverage reviews.